Portfolio News
Sofinnova MD Start
Moon Surgical appoints Anne Renevot as Chief Financial Officer
PARIS, FRANCE and SAN FRANCISCO, CA / ACCESSWIRE / May 3, 2023 / Moon Surgical, a French-American pioneer in collaborative robotics, today announced the appointment of Anne Renevot as the company's Chief Financial Officer (CFO). Anne brings over three decades of experience in public and private finance.
"We are delighted to welcome Anne as a key member of our executive leadership team," said Anne Osdoit, CEO of Moon Surgical and a Partner in Sofinnova Partners' medtech accelerator, MD Start. "Her financial expertise, gained from her tenure as CFO at fast-growing and innovative MedTech capital equipment companies such as EOS imaging will be crucial for shaping our financial operations to navigate an ever-changing economic environment."
"I am honored to join a company that has developed and manufactures the Maestro System in-house in Europe and the US, especially at this pivotal time as Moon Surgical prepares for a commercial launch," said Anne Renevot, CFO of Moon Surgical. "Being part of a company that offers a product with tangible impact on how surgeons treat patients is very exciting."
Prior to joining Moon Surgical, Anne Renevot was the CFO of Poxel, a publicly-traded French biotech company. Before that, she was CFO of EOS imaging, where she played a vital role in completing the company's €40 million IPO on NYSE Euronext Paris. Anne also held senior finance positions in manufacturing and international controlling at Cartier. She started her career at EY.
About Moon Surgical
Moon Surgical, based in Paris, France, and San Francisco, California, believes the future of the operating room lies in the hands of the empowered surgeon.
By equipping surgeons with complete control, renewed confidence, and technology adaptable to any situation, Moon Surgical strives to improve efficiency in operating rooms and provide better surgical care for patients. The minimalistic, co-manipulation Maestro System uses tomorrow's technology to deliver these vital skills to surgeons, today. www.moonsurgical.com
Contact
Investors and Media: info@moonsurgical.com
Moon Surgical® and Maestro® are registered trademarks of Moon Surgical, SAS
Related News
Muna Therapeutics Announces CEO Transition as Clinical Pipeline Advances
Partnership with French cancer research network FFCD expands Bioptimus’s STELA programme
Moon Surgical and Uncovr Announce First 20 Clinical Cases of Automated Operative Reporting on Maestro®
Mediar Therapeutics Announces First Cohorts Dosed in Phase 1 Clinical Trial of MTX-439 for Fibrosis Associated with Chronic Kidney Disease (CKD) and Additions to Clinical Advisory Board
TISSIUM secures €60 million to support commercial and clinical activities and platform expansion